Viking Therapeutics, Inc.
NASDAQ:VKTXBiotechnology
+$0.32 today
- Market cap
- $3.34B
- Beta
- 0.68
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$4.09
Volume 2.87M
Average 2.20M
VKTX Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Viking Therapeutics, Inc.NASDAQ: VKTX
Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026
Cost of revenue remains negative
Q2 FY2026 cost of revenue was $0, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $208K.
Context
- Cost of revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $52K.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 431K USD
- Year-over-year change
- —
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 431K | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Cost of Revenue vs competitors
How VKTX compares with its peers on the latest reported figures
- VKTX's LTM Jun 2026 cost of revenue of $208K is the 4th highest of the 7 companies compared; the peer median is $272.5K.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $109.42M | +470.7% | — | 8.5% | |
| LTM Jun 2026 | $559K | — | — | 7.9% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $421K | — | — | 0.4% |
| LTM Jun 2026 | $208K | — | — | — | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $124K | +24.0% | — | — |
| LTM Mar 2026 | $1K | -95.5% | — | 0.0% | |
KLRAKailera Therapeutics, Inc. | FY2025 | $0 | — | — | — |
| Peer median (excluding VKTX) | $272.5K | +24.0% | — | 4.1% | |
Competitors are the stored peer set for VKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 431K |
| Gross Profit | 0 | 0 | 0 | 0 | (431K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 44.98M | 54.23M | 63.81M | 101.64M | 344.96M |
| Selling, General & Admin | 10.7M | 16.12M | 37.02M | 49.28M | 48.39M |
| Operating Expenses | 55.68M | 70.36M | 100.83M | 150.92M | 393.34M |
| Depreciation & Amortization | 296K | 291K | 292K | 346K | 431K |
| EBITDA | (54.68M) | (68.52M) | (85.52M) | (109.52M) | (359.15M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (55.68M) | (70.36M) | (100.83M) | (150.92M) | (393.34M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 703K | 1.59M | 15.02M | 40.94M | 33.7M |
| Interest Expense | 18K | 59K | 88K | 94K | 0 |
| Other Income / Expenses | 692K | 1.49M | 14.93M | 40.96M | 33.7M |
| Income Before Tax | (54.99M) | (68.87M) | (85.9M) | (109.96M) | (359.64M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (54.99M) | (68.87M) | (85.9M) | (109.96M) | (359.64M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.70) | (0.88) | (0.91) | (1.01) | (3.19) |
| EPS (Diluted) | (0.70) | (0.88) | (0.91) | (1.01) | (3.19) |
| Weighted Avg Shares | 77.2M | 76.83M | 94.35M | 109.04M | 112.67M |
| Weighted Avg Shares (Diluted) | 77.2M | 76.83M | 94.35M | 109.04M | 112.67M |
Viking Therapeutics, Inc.
NASDAQ:VKTX
Intrinsic Alpha fair value
Locked
Current Price
$26.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.